This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Labopharm's (DDSS) mutually exclusive frustration with the Food and Drug Administration was balanced by positive study results from other health companies Friday, flattening stock indices at the end of the holiday-shortened week.

Labopharm was down $3.19, or 50.1%, to $3.11 after the drugmaker announced the FDA issued a second approvable letter saying the company hasn't demonstrated the efficacy of its once-daily formulation of pain-reliever Tramadol. Research firm Leerink Swann downgraded Labopharm from outperform to market perform Friday morning.

Labopharm competitor Biovail (BVF), which makes painkiller Ultram ER, offered news as well. It restated its 2004, 2005 and 2006 financial results in a filing with the Securities and Exchange Commission due to an error it found while preparing first-quarter results for 2007. Among a few other changes in the restatement, the company said it earned $1.32 a share rather than $1.27 in 2006, $1.54 a share instead of $1.48 in 2005 and $1 a share instead of $1.01 a share in 2004. Biovail shares were up $1.20, or 5%, to $25.46.

Other companies increased modestly after announcements of study results. Among them was Ista Pharmaceuticals (ISTA), which said the preliminary analysis of its phase IIb clinical trial of ecabet sodium, for dry eye, are positive. The trial is looking to confirm observations from prior clinical trials on the treatment and was not focusing on statistical significance. However, the company said ecabet sodium did achieve statistical significance in the Ocular Symptom Disease Index assessment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ENMD $1.18 1.72%
GENT $55.26 -0.88%
NVAX $8.88 0.11%
AAPL $130.50 -1.50%
FB $79.55 -1.20%

Markets

DOW 18,044.58 -187.44 -1.03%
S&P 500 2,107.23 -18.83 -0.89%
NASDAQ 5,038.3860 -50.9760 -1.00%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs